Neurocrine Biosciences (NBIX) Payables: 2010-2021
Historic Payables for Neurocrine Biosciences (NBIX) over the last 11 years, with Sep 2021 value amounting to $205.9 million.
- Neurocrine Biosciences' Payables rose 20.76% to $205.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $737.4 million, marking a year-over-year increase of 28.29%. This contributed to the annual value of $168.7 million for FY2020, which is 19.39% up from last year.
- Neurocrine Biosciences' Payables amounted to $205.9 million in Q3 2021, which was up 7.86% from $190.9 million recorded in Q2 2021.
- Neurocrine Biosciences' 5-year Payables high stood at $205.9 million for Q3 2021, and its period low was $852,000 during Q1 2017.
- Over the past 3 years, Neurocrine Biosciences' median Payables value was $141.3 million (recorded in 2019), while the average stood at $143.4 million.
- Per our database at Business Quant, Neurocrine Biosciences' Payables plummeted by 59.85% in 2017 and then surged by 5,257.98% in 2018.
- Over the past 5 years, Neurocrine Biosciences' Payables (Quarterly) stood at $53.5 million in 2017, then spiked by 61.39% to $86.4 million in 2018, then surged by 63.59% to $141.3 million in 2019, then rose by 19.39% to $168.7 million in 2020, then climbed by 20.76% to $205.9 million in 2021.
- Its Payables was $205.9 million in Q3 2021, compared to $190.9 million in Q2 2021 and $171.9 million in Q1 2021.